Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2000-01-10
2004-09-14
Shukla, Ram R. (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093700, C435S320100, C435S325000, C435S455000, C435S456000, C435S458000
Reexamination Certificate
active
06790442
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention relates to a genomic DNA, more particularly, a genomic DNA encoding a polypeptide capable of inducing the production of interferon-&ggr; (hereinafter abbreviated as “IFN-&ggr;”) by immunocompetent cells.
2. Description of the Prior Art
The present inventors successfully isolated a polypeptide capable of inducing the production of IFN-&ggr; by immunocompetent cells and cloned a cDNA encoding the polypeptide, which is disclosed in Japanese Patent Kokai No. 27,189/96 and 193,098/96. Because the present polypeptide possesses the properties of enhancing killer cells' cytotoxicity and inducing killer cells' formation as well as inducing IFN-&ggr;, a useful biologically active protein, it is expected to be widely used as an agent for viral diseases, microbial diseases, tumors and/or immunopathies, etc.
It is said that a polypeptide generated by a gene expression may be partially cleaved and/or glycosylated by processing with intracellular enzymes in human cells. A polypeptide to be used in therapeutic agents should be preferably processed similarly as in human cells, whereas human cell lines generally have a disadvantage of less producing the present polypeptide, as described in Japanese Patent Application No.269,105/96. Therefore, recombinant DNA techniques should be applied to obtain the present polypeptide in a desired amount. To produce the polypeptide processed similarly as in human cells using recombinant DNA techniques, mammalian cells should be used as the hosts.
SUMMARY OF THE INVENTION
In view of foregoing, the first object of the present invention is to provide a DNA which efficiently expresses the polypeptide production when introduced into a mammalian host cell.
The second object of the present invention is to provide a transformant into which the DNA is introduced.
The third object of the present invention is to provide a process for preparing a polypeptide, using the transformant.
[Means to Attain the Object]
The present inventors' energetic studies to attain the above objects succeeded in the finding that a genomic DNA encoding the present polypeptide efficiently expresses the polypeptide production when introduced into mammalian host cells. They found that the polypeptide thus obtained possessed significantly higher biological activities than that obtained by expressing a cDNA encoding the polypeptide in
Escherichia coli.
The first object of the present invention is attained by a genomic DNA encoding a polypeptide with the amino acid sequence of SEQ ID NO:1 (where the symbol “Xaa” means “isoleucine” or “threonine”) or its homologous one, which induces interferon-&ggr; production by immunocompetent cells.
The second object of the present invention is attained by a transformant formed by introducing the genomic DNA into a mammalian host cell.
The third object of the present invention is attained by a process for preparing a polypeptide, which comprises (a) culturing the transformant in a nutrient medium, and (b) collecting the polypeptide from the resultant culture.
REFERENCES:
patent: 5166066 (1992-11-01), Carter
patent: 0692536 (1996-01-01), None
patent: 0712931 (1996-05-01), None
patent: 0712931 (1996-05-01), None
patent: 0861663 (1998-02-01), None
G Romano et al., Stem Cells, “Latest Developments in Gene Transfer Technology: Achievements, Perspectives, and Controversies over Therapeutic Applications,” 2000, 18:19-39.*
J Golab, Cytokine, “Interleukin 18—Interferon beta inducing Factor—A Novel Player in Tumour Immunotherapy?,” Apr. 2000, vol. 12, No. 4, pp. 332-338.*
WF Anderson, Nature, “Human gene therapy,” Apr. 1998, vol. 392, Supp., pp. 25-30.*
Ushio et al., “Cloning of the CDNA for human IF-N&ggr;-inducing factor, expression inEscherichia coli, and studies on the biologic activities of the protein”,The Journal of Immunology, vol. 156: 11 pages 4274-4279 (Jun. 1, 1996).
Ballast et al., “Characterization and chromosomal localizationof the human interleukin-18 gene”,BLOOD, vol. 90, No. 10, part 2 suppl. 1 p. 177b (Nov. 15, 1997).
Minowada, “Leukemia Cell Lines”,Cancer Review, vol. 10, pp. 1-18, 1988.
Hay et al., “Cell Lines and Hybridomas”,ATCC, Eighth Edition, pp. 127, 129, 131, 152, 207, 339, 1994.
Kostura et al., “Indentification of a Monocyte Specific Pre-Interleukin 1B Convertase Activity”,Proc. Natl. Acad. Sci. USA, vol. 86, pp. 5227-5231, Jul. 1989.
Shimada et al., “Basic Techniques for Gene Therapy”,Biomanual Up Series, 1996.
Yokota et al., “The Experimental Methods for the Gene Cloning”,Biomanual Series 3, 1993.
Kuriki et al., “The Handbook for the Cell Engineering”, Saibo-Kagaku Handbook, 1992.
Rothe, H., et al. (1997)J. Clin. Invest. 99: 469-74.
Nolan, K.F., et al. (1998)Genomics51: 161-63.
Kurimoto Masashi
Okura Takanori
Torigoe Kakuji
Browdy and Neimark PLLC
Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
Shukla Ram R.
LandOfFree
Genomic DNA encoding a polypeptide capable of inducing the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Genomic DNA encoding a polypeptide capable of inducing the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Genomic DNA encoding a polypeptide capable of inducing the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3267455